Current biodefense vaccine programs and challenges

 Abstract

The Defense Threat Reduction Agency’s Joint Science and Technology Office manages the Chemical and Biological Defense Program’s Science and Technology portfolio. The Joint Science and Technology Office’s mission is to invest in transformational ideas, innovative people and actionable technology development for Chemical and Biological Defense solutions, with the primary goal to deliver Science and Technology products and capabilities to the warfighter and civilian population that outpace the threat. This commentary focuses on one thrust area within this mission: the Vaccine program of the Joint Science and Technology Office’s Translational Medical Division. Here, we will describe candidate vaccines currently in the S&T pipeline, enabling technologies that should facilitate advanced development of these candidates into FDA licensed vaccines, and how the ever-changing biological threat landscape impacts the future of biodefense vaccines.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
1591 - 1597
doi
10.4161/hv.24063
Type
Special Focus Commentary
Group
Special Focus VR6
 Metrics
 Cite This Article
 Permissions
Creative Commons License Permissions
 Reprints
Current biodefense vaccine programs and challenges